Skip to content
Psychedelic Alpha· Josh·· 11 days agoPickAI score80

Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

AI summary

Compass Pathways announced it has submitted a to the for its COMP360 psilocybin for (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.

Why it matters

With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.

Key facts

Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways
Jurisdiction
United States
Participants
more than 1,000 participants (as written in the text)
Source
Psychedelic Alpha (psychedelicalpha.com)
Published
How this summary was made

The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Psychedelic Alpha · psychedelicalpha.com

Connected to

Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways
Jurisdiction
United States

Other recent items on these topics